Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria

Prior treatment

• Participation in any clinical drug trial in the 2 months prior to the initial visit.
• Surgical or percutaneous occlusion of the left atrial appendage or intention to perform such intervention at the time of inclusion.

Other illness

• Moderate or severe hepatic insufficiency (Defined as grade B or C of the Child-Pugh classification.

Lab values

• Creatinine clearance according to the CKD-EPI formula less than 15 ml/min/m2

Other

• Contraindication to receive Edoxaban according to the Technical Data Sheet.
• Absence of recorded patient or treatment information.
• Any circumstance that, in the opinion of the investigator, affects patient follow-up (including life expectancy of less than two years or inability to perform follow-up).
• Persons who are legally incapacitated or unable to understand informed consent.

• Patients 75 years of age or older with a diagnosis of NVAF.
• Patients in whom treatment had been started in the 6 months prior to enrollment in the study with Edoxaban for prevention of stroke and systemic embolism after diagnosis of NVAF and according to the drug's technical data sheet.
• Frailty criteria according to the FRAIL scale (score of 3 to 5 points).
• Written informed consent to participate in the study prior to any intervention.